These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 37219538)
1. SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties. Warren MC; Matissek S; Rausch M; Panduro M; Hall RJ; Dulak A; Brennan D; Das Yekkirala S; Koseoglu S; Masia R; Yang Y; Reddy N; Prenovitz R; Strand J; Zaidi T; Devereaux E; Foissac CJ; Stagg J; Lee BH; Holland P; Palombella VJ; Lake AC Immunohorizons; 2023 May; 7(5):366-379. PubMed ID: 37219538 [TBL] [Abstract][Full Text] [Related]
2. Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism. Spatola BN; Lerner AG; Wong C; Dela Cruz T; Welch M; Fung W; Kovalenko M; Losenkova K; Yegutkin GG; Beers C; Corbin J; Soros VB MAbs; 2020; 12(1):1838036. PubMed ID: 33146056 [TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity. Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609 [TBL] [Abstract][Full Text] [Related]
4. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184 [TBL] [Abstract][Full Text] [Related]
5. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy. Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716 [TBL] [Abstract][Full Text] [Related]
7. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape. Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024 [TBL] [Abstract][Full Text] [Related]
11. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420 [TBL] [Abstract][Full Text] [Related]
13. IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells. Noble A; Mehta H; Lovell A; Papaioannou E; Fairbanks L Eur J Immunol; 2016 Jun; 46(6):1438-48. PubMed ID: 26990545 [TBL] [Abstract][Full Text] [Related]
14. CD39/CD73/A2AR pathway and cancer immunotherapy. Xia C; Yin S; To KKW; Fu L Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386 [TBL] [Abstract][Full Text] [Related]
15. Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation. Festag J; Thelemann T; Schell M; Raith S; Michel S; Jaschinski F; Klar R Mol Ther Nucleic Acids; 2020 Sep; 21():656-669. PubMed ID: 32739778 [TBL] [Abstract][Full Text] [Related]
16. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73. Kumar M; Lowery R; Kumar V SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease. Geraghty NJ; Watson D; Sluyter R Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314 [TBL] [Abstract][Full Text] [Related]
19. Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma. Sun T; Li Y; Yang Y; Liu B; Cao Y; Yang W Cell Death Dis; 2022 Oct; 13(10):875. PubMed ID: 36245000 [TBL] [Abstract][Full Text] [Related]
20. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8 Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]